We have entered into an exclusive agreement with Takeda to promote and distribute QDENGA®, India’s first CDSCO-approved dengue vaccine, anticipated to be available in the first half of 2027.
Read more: tinyurl.com/48khdxd7#DrReddys#DenguePrevention
Immuno-oncology is opening new possibilities in cancer care. At Abhinandan, G.V. Prasad, leaders and our teams engaged with investigators and advisors on scientific rigor, collaboration, and patient access.
#DrReddys#WeareDrReddys#CancerCare#GoodHealthCantWait
With the first-to-market launch of Sugammadex Injection, a generic equivalent of Bridion®, in the U.S., we continue expanding our hospital portfolio, reinforcing our commitment to improving patient access to affordable, high-quality medicines.
#DrReddys#GoodHealthCantWait
🎉 Exciting news! @drreddys has joined the @AFSAcollab!
We're proud to partner with Dr. Reddy's Laboratories to help advance animal-free science & accelerate the adoption of human-relevant, non-animal methods in drug development & testing.
Welcome to the #AFSAFamily, @drreddys!
As an organization, the cornerstone of our work is closely aligned with our founder’s values, creating access and enabling livelihoods. Our CSR team takes this forward, through initiatives in various areas. #DrReddys#CSR#SpiritOfGiving#GoodHealthCantWait
Launching our 3rd whitepaper, ‘Translational Research Ecosystem: Learnings from the World & Building for India,' from our joint roundtable with Dr. Reddy’s Institute of Life Sciences (DRILS), moderated by Citeline. #GoodHealthCantWait#WeAreDrReddys#TranslationalResearch
We have partnered with Ramdevrao Hospital to establish a Cath Lab in Kukatpally, Hyderabad, expanding local access to advanced cardiac imaging and care , helping address delays in treatment and easing the burden of travel for care. #DrReddys#CSR#HealthcareAccess#CardiacCare
ALT Anuradha Gunupati, Founder Trustee, Dr. Reddy's Foundation, inaugurating facility along with Randhir Kumar, Head Company Secretary & CSR and officials from the hospital
With the first-to-market launch of Bosutinib tablets, 400 mg in the U.S., in collaboration with MSN Laboratories Pvt. Ltd., we are strengthening our oncology portfolio while improving patient access to affordable, high-quality medicines. #WeAreDrReddys#GoodHealthCantWait
Marking 25 years of Dr. Reddy’s Laboratories’ NYSE listing (RDY), Chairman Satish Reddy rang The Closing Bell® at the @NYSE today, joined by leadership and colleagues.
Source: NYSE
#DrReddys#WeAreDrReddys#NYSE#GoodHealthCantWait
We were at the Nasdaq Opening Bell ceremony in Times Square, New York, on May 26, 2026. The invitation followed recent recognition of our corporate governance by IiAS, BSE, and the International Finance Corporation (IFC).
#DrReddys#WeAreDrReddys#GoodHealthCantWait